# A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

> **NCT07103668** · PHASE3 · RECRUITING · sponsor: **Suzhou Immunofoco Biotechnology Co., Ltd** · enrollment: 150 (estimated)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** CAR T cells
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT07103668
- **Lead sponsor:** Suzhou Immunofoco Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07103668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07103668, "A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07103668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*